Harrow
Logotype for Harrow Inc

Harrow (HROW) investor relations material

Harrow Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Harrow Inc
Jefferies Global Healthcare Conference summary18 Nov, 2026

Financial performance and growth

  • Five-year revenue CAGR exceeded 40%; adjusted EBITDA CAGR exceeded 60%. FY2026 revenue guidance is $350M–$365M, midpoint $357.5M, vs. $272.3M in FY2025.

  • Q3 2026 was a record: revenue exceeded $99M, including $83.5M branded revenue at nearly 80% gross margin; cash was ~$75M at quarter-end.

  • Q4 2026 adjusted EBITDA guidance exceeded $33M, vs. $21.2M recently reported; $300M unsecured notes carry an 8.625% coupon and mature in about four years.

Core brands

  • VEVYE generated nearly $40M in Q3 2026 revenue, up 75% YoY; prescriptions rose 83% YoY and revenue increased 35% QoQ. IP extends to 2039.

  • VEVYE is a water-free cyclosporine formulation delivering ~22x more cyclosporine to the inflammation site than the vehicle in RESTASIS; 10.7M new commercial lives are expected to become accessible Jan. 1.

  • IHEEZO generated >$25M in Q3 2026 revenue, up 15%; unit demand rose 21% YoY despite losing cataract-surgery pass-through status at end-Q1. Net price rose 25% July 1.

  • Management expects Q4 2026 to be IHEEZO's strongest quarter to date; QUELL data showed less pain, ocular surface damage and adverse events 4–24 hours after topical anesthesia vs. injected lidocaine.

  • TRIESENCE revenue exceeded $10M in Q3 2026, up 186%, with unit demand up 110%; coverage exceeds 95% and patient out-of-pocket cost is ~$38.

Operating leverage

  • SG&A was 84% of revenue in H1 2026 and 54% in Q3; Q3 revenue rose 41% while SG&A was flat QoQ.

  • Of the ~$28M Q2-to-Q3 revenue increase, $22M flowed to profit, a 78% conversion; management expects costs to grow more slowly than revenue in coming quarters.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Harrow earnings date

Logotype for Harrow Inc
Q4 20262 Mar, 2027
Harrow
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Harrow earnings date

Logotype for Harrow Inc
Q4 20262 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Harrow Health Inc is a pharmaceutical company focused on the development and commercialization of ophthalmic pharmaceutical products. The company offers compounded medications and branded formulations for use in eye care. It serves physicians, clinics, and surgical centers in the United States. The company is headquartered in Nashville, Tennessee, and its shares are listed on the NASDAQ.